Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
about
Voriconazole therapeutic drug monitoring.Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Voriconazole pharmacokinetics in liver transplant recipients.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismRational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsPharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.Pharmacokinetics of antifungal agents in children.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Antifungal agents--clinical pharmacokinetics and drug interactions.Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013Antifungal therapeutic drug monitoring: established and emerging indications.New and investigational triazole agents for the treatment of invasive fungal infections.Voriconazole therapeutic drug monitoring: focus on safety.Safety of triazole antifungal drugs in patients with cancer.Prophylactic antifungal agents used after lung transplantation.Opportunistic invasive fungal infections: diagnosis & clinical management.Therapeutic drug monitoring of voriconazole and posaconazole.Pharmacogenomics of the triazole antifungal agent voriconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Photosensitizing medications and photocarcinogenesis.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.PharmGKB summary: voriconazole pathway, pharmacokinetics.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.
P2860
Q24542411-DA6E42A3-9753-414D-ADCC-B9BC06ADACF1Q30981299-0DB2E20F-31B2-4535-AF91-D5E317DE874DQ33608028-32E8F125-4F5B-41A7-9029-AA371AA11EA2Q33613685-2BEDBF21-028D-4D79-A169-6309829F4F96Q33849298-C6A4ADCC-2D90-450D-BAB4-8D545A94588FQ34138276-71611688-67B1-4251-9EBD-637F3396043DQ34213621-C7E9EF4F-7F00-4E5A-AC3E-6E5D6459BF48Q34233142-2068CBDA-038E-4D79-9662-EBDBBD2ACE24Q34505582-A9F5AE9E-119E-4BA1-B92B-70F1546EA044Q35086478-46D8B051-A2B6-4CF7-81D3-0722BAF87E35Q35270270-E8D2AC92-5585-4F1B-934D-CF107A634299Q35617587-DAFAB008-A345-424A-8441-48B229412804Q35635830-1C09635A-569B-4748-B319-1F21B9A0C5B8Q35647746-072FDA10-9365-453E-8A84-E3CE56054B18Q35959476-C9A17773-0381-4612-A233-7ABBBA2823BFQ36163345-1548BFBD-6FBB-42E2-B8A7-6C420463FB2CQ36273788-8653C489-81EC-4EF1-85EB-C7655028A568Q36521993-E94B1366-BF0C-4704-A1E7-DA07A74FCAE8Q36608562-EE4D77F2-1A56-4809-9553-756F2E3925A1Q37157893-B8417C61-99A2-4832-8486-22679DDA9FE3Q37159568-0C1CA56B-4E90-46A4-8C06-88FDDEBBF3C6Q37233505-A5067FB1-5AA3-4C52-86B2-D3D89803BF68Q37310029-38880319-1123-4A01-B589-D1EA23191355Q37364295-8DA9EE9A-855C-4828-B717-4EF848AE9D14Q37658869-C740B9F3-0CF1-47FB-A52D-BB890BCE0EDCQ37662650-05D2ED89-CC9A-480A-86E5-C15027F8F650Q37697380-D76D61FE-5517-46D7-AB7A-78FAC26B34E0Q37726198-0B7C7524-0EF0-458D-972B-40B58223DB68Q37833074-9271A486-7C3A-4145-B127-7D08FF5F4905Q37892536-D7523002-7DAD-4932-BA99-9D241F4EE327Q37904672-F35C2C0C-8061-4CEE-B4FF-61C2B1E8E19BQ38140015-1CA6F604-5324-4FD4-840D-4282CDFDC307Q38176091-54082912-1777-43FB-B38C-852FC90E7C59Q38193337-EC9C2F48-08D4-4E51-8A19-3CE2379523C3Q38284468-5730961D-13A1-4126-A727-F25CEBA2C0B1Q38775809-D0807920-FD29-4AD3-87C0-DF0589C1FF89Q38880522-7FC1D60C-DA7D-4810-A82E-4ADE14A79C93Q38889189-C3976019-2F1F-4448-8753-ABE3A2C49D97Q38918175-A9CB7A7F-641E-4378-B27F-302342CFC524Q39215244-87D6B8D4-BACD-4521-BACB-FC52D842E6AA
P2860
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@en
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@nl
type
label
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@en
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@nl
prefLabel
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@en
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@nl
P2093
P1476
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
@en
P2093
Kaneo Sekiguchi
Kazunao Kondo
Kazuo Umemura
Mitsuyoshi Nakashima
So Miyoshi
Yasuhiko Ikeda
P304
P356
10.1016/J.CLPT.2004.02.002
P407
P577
2004-06-01T00:00:00Z